Solara Active Pharma Sciences Ltd
Thu 11/09/2025,11:59:55 | NSE : SOLARA
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 665.00
Previous Close
₹ 663.95
Volume
56791
Mkt Cap ( Rs. Cr)
₹3054.00
High
₹ 688.00
Low
₹ 662.20
52 Week High
₹ 882.80
52 Week Low
₹ 442.80
Book Value Per Share
₹ 245.77
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Solara Active Pharma Sciences Ltd
Your Vote -
Buy
88.24%
Hold
5.29%
Sell
6.47%
88.24%
170 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
43%
Sell Order Quantity
57%
Bid Price
Qty
687.70
6
688.00
5
688.00
6
688.00
12
687.00
1
Bid Total
19841
Bid Price
Qty
688.25
2
689.00
12
689.00
12
689.00
10
689.00
53
Bid Total
26117
Option Chain
Analyzes market sentiment, predicts Solara Active Pharma Sciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Solara Active Pharma - Copy of Newspaper Publication
-
Solara Active Pharma - General Updates
-
Solara Active Pharma - Business Responsibility and Sustainability Reporting (BRSR)
-
Solara Active Pharma - Reg. 34 (1) Annual Report.
-
Solara Active Pharma - Shareholders meeting
-
Solara Active Pharma - Notice Of The 8Th Annual General Meeting
-
Solara Active Pharma - Copy of Newspaper Publication
-
Solara Active Pharma - Updates
-
Solara Active Pharma - Intimation Regarding 100 Days Campaign - Saksham Niveshak
-
Solara Active Pharma - Receipt Of Call Money Pursuant To The First Reminder Notice Issued For Payment Of First Call Money On
-
Solara Active Pharma - Updates
-
Solara Active Pharma - Monitoring Agency Report
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
-
Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Solara Active Pharma - Copy of Newspaper Publication
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Solara Active Pharma - Press Release
-
Solara Active Pharma posts Q1 net profit of Rs 10.53 cr
-
Solara Active Pharma - Statement of deviation(s) or variation(s) under Reg. 32
-
Solara Active Pharma - Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30
-
Solara Active Pharma - Outcome of Board Meeting
-
Solara Active Pharma - Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30, 2025.
-
Solara Active Pharma - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended
-
Solara Active Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Solara Active Pharma - Analysts/Institutional Investor Meet/Con. Call Updates
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Solara Active Pharma - Board Meeting Intimation
-
Solara Active Pharma - Board Meeting Intimation for Quarter Ended June 30, 2025 Under SEBI Listing Regulations
-
Solara Active Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Solara Active Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Solara Active Pharma - Copy of Newspaper Publication
-
Solara Active Pharma - Copy of Newspaper Publication
-
Solara Active Pharma - Updates
-
Solara Active Pharma - Dispatch Of First Reminder Notice For Payment Of First Call Money
-
Solara Active Pharma - Credit Rating
-
Solara Active Pharma - Announcement under Regulation 30 (LODR)-Credit Rating
-
Solara Active Pharma - Trading Window-XBRL
-
Solara Active Pharma - Trading Window
-
Solara Active Pharma - Disclosure under SEBI Takeover Regulations
-
Solara Active Pharma
-
Solara Active Pharma successfully completes EU GMP Inspection
-
Stock Update: Solara Active Pharma Science
-
Solara Active Pharma Sciences Q2Fy22 results
-
Solara Active Pharma Sciences: Q1FY22 Results update
-
Solara Active Pharma Sciences Q1FY2022
-
Solara announces CEP for Ranitidine Hydrochloride drug substance restored by EDQM
-
Solara Active Pharma Sciences
-
Solara Active Pharma Sciences
-
Solara Active Pharma Sciences: Q4FY2021 Result Update
-
Stock update - Solara Active Pharma Sciences
-
Solara Active Pharma Sciences board approves merger of Aurore Life sciences
-
Solara Active Pharma Sciences
-
Solara Active Pharma Sciences
-
Solara Active Pharma Sciences : Stock Update
-
Solara Active Pharma announces interim dividend
-
Solara Active Pharma reports good Q2 earnings
-
Solara Active Pharma Sciences
-
New Idea - Solara Active Pharma Sciences
-
Solara Active Pharma completes USFDA inspection at SRC
Key fundamentals
Evaluate the intrinsic value of Solara Active Pharma Sciences Ltd stock
Name | March-25 | March-24 | March-23 | March-22 | March-21 |
---|---|---|---|---|---|
Assets | 1872.27 | 1936.8 | 2504.28 | 2551.62 | 2108.49 |
Liabilities | 1872.27 | 1936.8 | 2504.28 | 2551.62 | 2108.49 |
Equity | 40.25 | 36 | 36 | 36 | 35.92 |
Gross Profit | 203.84 | -95.06 | 134.04 | 80.35 | 385.33 |
Net Profit | -1.08 | -566.87 | -22.21 | -58.56 | 220.96 |
Cash From Operating Activities | 212.8 | 110.95 | 156.17 | -241.77 | 154.44 |
NPM(%) | -0.08 | -43.98 | -1.53 | -4.61 | 13.66 |
Revenue | 1283.76 | 1288.92 | 1443.81 | 1268.34 | 1616.88 |
Expenses | 1079.92 | 1383.98 | 1309.77 | 1187.99 | 1231.55 |
ROE(%) | -0.09 | -51.86 | -2.03 | -5.35 | 20.21 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
18 Aug 2021 | 3 | 30 | 0 | 1648.75 |
19 Nov 2020 | 4 | 40 | 0 | 1095.5 |
28 Jul 2020 | 2 | 20 | 0 | 502.4 |
06 Aug 2019 | 5 | 50 | 0 | 442.1 |
Peers
Other companies within the same industry or sector that are comparable to Solara Active Pharma Sciences Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 810.85 | 0.88 | 73.51 | 378.79 | 301.39 | 0.62 |
Lotus Eye Hospital and Institute Ltd | 120.00 | -1.15 | 387.10 | 1380.25 | 3.55 | 0.00 |
Vaishali Pharma Ltd | 12.09 | 0.33 | 403.00 | 711.43 | 3.13 | 0.00 |
Astec Lifesciences Ltd | 855.00 | 0.30 | 0.00 | 1301.61 | -604.77 | 0.00 |
Company Info
Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, “it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.
Our Company was originally incorporated on February 23, 2017 under the Companies Act, 2013 as SSL Pharma Sciences Limited with the RoC. The name of the Company was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC on March 25, 2017. 2019 -Solara Active Pharma Sciences Limited said that, “it has successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with ZERO 483s i 2021 -Solara Active Pharma approves acquisition of balance 10.77% stake in Sequent Penems 2023 -Solara Active Pharma Sciences completes WHO inspection at its Cuddalore facility. 2024 -The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.
Read More
Parent Organisation
Solara Active Pharma Sciences Ltd.
Founded
23/02/2017
Managing Director
Mr.Poorvank Purohit
NSE Symbol
SOLARAEQ
FAQ
The current price of Solara Active Pharma Sciences Ltd is ₹ 686.75.
The 52-week high for Solara Active Pharma Sciences Ltd is ₹ 688.00 and the 52-week low is ₹ 662.20.
The market capitalization of Solara Active Pharma Sciences Ltd is currently ₹ 3054.00. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Solara Active Pharma Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Solara Active Pharma Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Solara Active Pharma Sciences Ltd shares.
The CEO of Solara Active Pharma Sciences Ltd is Mr.Poorvank Purohit, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.